MX2021015942A - Composiciones y métodos para tratar trastornos del snc. - Google Patents

Composiciones y métodos para tratar trastornos del snc.

Info

Publication number
MX2021015942A
MX2021015942A MX2021015942A MX2021015942A MX2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cns disorders
treating cns
ilib
Prior art date
Application number
MX2021015942A
Other languages
English (en)
Inventor
Francesco G Salituro
María Jesús Blanco-Pillado
Marshall Lee Morningstar
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021015942A publication Critical patent/MX2021015942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids

Abstract

En el presente documento se proporciona un compuesto de Fórmula I, II, IIIa, IIIb, V, VIa, VIb, VII, VIII, IX o XI: (ver fórmula) o una sal farmacéuticamente aceptable de este, composiciones farmacéuticas que comprenden un compuesto de Fórmula I, II, IIIa, IIIb, V, VIa, VIb, VII, VIII, IX, o X y métodos de uso de los compuestos, p. ej., en el tratamiento de trastornos del SNC.
MX2021015942A 2019-06-27 2020-06-29 Composiciones y métodos para tratar trastornos del snc. MX2021015942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867618P 2019-06-27 2019-06-27
PCT/US2020/040153 WO2020264509A1 (en) 2019-06-27 2020-06-29 Compositions and methods for treating cns disorders

Publications (1)

Publication Number Publication Date
MX2021015942A true MX2021015942A (es) 2022-04-18

Family

ID=71728947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015942A MX2021015942A (es) 2019-06-27 2020-06-29 Composiciones y métodos para tratar trastornos del snc.

Country Status (13)

Country Link
US (1) US20230303616A9 (es)
EP (1) EP3990469A1 (es)
JP (1) JP2022538299A (es)
KR (1) KR20220038680A (es)
CN (1) CN114391019A (es)
AR (1) AR119305A1 (es)
AU (1) AU2020302748A1 (es)
BR (1) BR112021026462A2 (es)
CA (1) CA3143509A1 (es)
IL (1) IL289172A (es)
MX (1) MX2021015942A (es)
TW (1) TW202114700A (es)
WO (1) WO2020264509A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
JOP20210293A1 (ar) 2019-05-31 2023-01-30 Sage Therapeutics Inc ستيرويدات ذات فعالية عصبية وتركيبات منها

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20090118248A1 (en) * 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
EP3909966A1 (en) * 2013-04-17 2021-11-17 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
MX2020006608A (es) * 2017-12-22 2020-11-06 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
CN113383004A (zh) * 2018-12-05 2021-09-10 萨奇治疗股份有限公司 神经活性类固醇及其使用方法

Also Published As

Publication number Publication date
CN114391019A (zh) 2022-04-22
AU2020302748A1 (en) 2022-01-06
CA3143509A1 (en) 2020-12-30
JP2022538299A (ja) 2022-09-01
TW202114700A (zh) 2021-04-16
US20230303616A9 (en) 2023-09-28
WO2020264509A1 (en) 2020-12-30
AR119305A1 (es) 2021-12-09
US20220380405A1 (en) 2022-12-01
IL289172A (en) 2022-02-01
BR112021026462A2 (pt) 2022-03-15
EP3990469A1 (en) 2022-05-04
KR20220038680A (ko) 2022-03-29

Similar Documents

Publication Publication Date Title
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12017501326A1 (en) Tgf-� inhibitors
MX2021015605A (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
SG11201907945YA (en) Azetidine derivative
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
MX2021007258A (es) Composiciones de esparsentan amorfas.
MX2023006063A (es) Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central.
MX2021010880A (es) Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
MX2021014458A (es) Compuestos triciclicos.
MX2021014941A (es) Inhibidores de dopamina-b-hidroxilasa.
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.